Skip to main content
Premium Trial:

Request an Annual Quote

Axys Identifies Genes, Functions for Parke-Davis

Premium

SOUTH SAN FRANCISCO, Calif.--Axys Pharmaceuticals announced that is has successfully completed the transfer of its proprietary bioinformatics platform to and attained two separate milestones in its psychiatric genomics collaboration with the Parke-Davis Pharmaceutical Research division of Warner Lambert. Tim Harris, Axys's senior vice-president of research, said the company has transferred to Parke-Davis a set of robust software tools that integrate genetic, genomic, and biological data to help researchers integrate and maintain key public and proprietary information on genes of interest.

The companies initiated a gene identification and function research collaboration in the area of schizophrenia and bi polar disorder in November 1997. Wendell Wierenga, Parke-Davis's senior vice-president, said the milestone "represents a significant advance toward understanding the causes of these psychiatric disorders." He added, "The bioinformatics software will serve as a key component in our overall drug discovery efforts."

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.